instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myalgia'. | Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial.
Neoadjuvant radiotherapy with or without chemotherapy decreases the risk of local recurrence after surgery for rectal cancer. Emerging data suggest that diabetic patients on metformin may have improved c... | METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34401534 | 20,198,293 | 2021-09 |
What was the dosage of drug 'CAPECITABINE'? | Metformin with neoadjuvant chemoradiation to improve pathologic response in rectal cancer: A pilot phase I/II trial.
Neoadjuvant radiotherapy with or without chemotherapy decreases the risk of local recurrence after surgery for rectal cancer. Emerging data suggest that diabetic patients on metformin may have improved c... | 825 MILLIGRAM/SQ. METER, BID | DrugDosageText | CC BY-NC-ND | 34401534 | 20,198,307 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal impairment'. | AL Amyloidosis Presenting With Crescentic Glomerulonephritis.
Kidney amyloidosis typically presents with nephrotic-range proteinuria. Rare cases of crescentic glomerulonephritis have been reported in patients with kidney amyloidosis but most cases were in the setting of patients with AA amyloidosis from long-standing i... | BORTEZOMIB, CARFILZOMIB, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 34401730 | 19,791,563 | 2021 |
What was the dosage of drug 'BORTEZOMIB'? | AL Amyloidosis Presenting With Crescentic Glomerulonephritis.
Kidney amyloidosis typically presents with nephrotic-range proteinuria. Rare cases of crescentic glomerulonephritis have been reported in patients with kidney amyloidosis but most cases were in the setting of patients with AA amyloidosis from long-standing i... | 7 CYCLES | DrugDosageText | CC BY-NC-ND | 34401730 | 19,791,563 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperviscosity syndrome'. | Multiple Myeloma, Hyperviscosity, Hemodialysis Filter Clogging, and Antigen Excess Artifact: A Case Report.
Kidney involvement in multiple myeloma can result in kidney failure. Unlike Waldenström macroglobulinemia, hyperviscosity syndrome is a rare occurrence in multiple myeloma. Timely detection of hyperviscosity synd... | BORTEZOMIB, CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE | DrugsGivenReaction | CC BY | 34401731 | 19,790,485 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Plasma cell myeloma'. | Multiple Myeloma, Hyperviscosity, Hemodialysis Filter Clogging, and Antigen Excess Artifact: A Case Report.
Kidney involvement in multiple myeloma can result in kidney failure. Unlike Waldenström macroglobulinemia, hyperviscosity syndrome is a rare occurrence in multiple myeloma. Timely detection of hyperviscosity synd... | BORTEZOMIB, CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE | DrugsGivenReaction | CC BY | 34401731 | 19,790,485 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombosis in device'. | Multiple Myeloma, Hyperviscosity, Hemodialysis Filter Clogging, and Antigen Excess Artifact: A Case Report.
Kidney involvement in multiple myeloma can result in kidney failure. Unlike Waldenström macroglobulinemia, hyperviscosity syndrome is a rare occurrence in multiple myeloma. Timely detection of hyperviscosity synd... | BORTEZOMIB, CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE | DrugsGivenReaction | CC BY | 34401731 | 19,790,485 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | ACYCLOVIR, CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, EVEROLIMUS, FLUDARABINE PHOSPHATE, GEMCITABINE, MYCOPHENOLATE MOFETIL, OMEPRAZOLE, PREDNISONE, RITUXIMAB, TISAGENLECLEUCEL, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN, EVEROLIMUS, GEMCITABINE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34401733 | 20,319,870 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | ACYCLOVIR, CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, EVEROLIMUS, FLUDARABINE PHOSPHATE, GEMCITABINE, MYCOPHENOLATE MOFETIL, OMEPRAZOLE, PREDNISONE, RITUXIMAB, TISAGENLECLEUCEL, VINCRISTINE SULFATE | DrugsGivenReaction | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the administration route of drug 'RITUXIMAB'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | Other | DrugAdministrationRoute | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the administration route of drug 'TISAGENLECLEUCEL'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | Other | DrugAdministrationRoute | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the dosage of drug 'DOXORUBICIN HYDROCHLORIDE'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | THREE CYCLES; AS PART OF R-CHOP | DrugDosageText | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the dosage of drug 'DOXORUBICIN'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | UNK, 3 CYCLES | DrugDosageText | CC BY-NC-ND | 34401733 | 20,319,870 | 2021 |
What was the dosage of drug 'EVEROLIMUS'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | INITIAL DOSAGE NOT STATED. LATER REDUCED TO 50% AND FINALLY IT WAS STOPPED | DrugDosageText | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | INITIAL DOSAGE NOT STATED. LATER, MOFETIL DOSE WAS DECREASED TO 50% | DrugDosageText | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the dosage of drug 'VINCRISTINE SULFATE'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | THREE CYCLES; AS PART OF R-CHOP | DrugDosageText | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
What was the dosage of drug 'VINCRISTINE'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | UNK, 3 CYCLES | DrugDosageText | CC BY-NC-ND | 34401733 | 20,319,870 | 2021 |
What was the outcome of reaction 'Acute kidney injury'? | Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a newer and effective therapeutic option approved for patients with relapsed/refractory acute lymphoblastic leukemia and diffuse large ... | Recovering | ReactionOutcome | CC BY-NC-ND | 34401733 | 20,333,779 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis allergic'. | Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco.
Coronary artery vasospasm is typically managed through avoidance of triggers and with symptomatic treatments with calcium channel blockers and long-acting nitrates. Here, we report a rare case of medically refractory coronary a... | NICOTINE | DrugsGivenReaction | CC BY-NC-ND | 34401754 | 19,800,544 | 2021-08-04 |
What was the dosage of drug 'NICOTINE'? | Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco.
Coronary artery vasospasm is typically managed through avoidance of triggers and with symptomatic treatments with calcium channel blockers and long-acting nitrates. Here, we report a rare case of medically refractory coronary a... | PATCH | DrugDosageText | CC BY-NC-ND | 34401754 | 19,800,544 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute myocardial infarction'. | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | BEZAFIBRATE, EDOXABAN TOSYLATE, LANSOPRAZOLE, MOSAPRIDE | DrugsGivenReaction | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coronary artery embolism'. | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | BEZAFIBRATE, EDOXABAN TOSYLATE, LANSOPRAZOLE, MOSAPRIDE | DrugsGivenReaction | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the dosage of drug 'BEZAFIBRATE'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | 400MG/DAY | DrugDosageText | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the dosage of drug 'EDOXABAN TOSYLATE'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | 60MG/DAY | DrugDosageText | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the dosage of drug 'LANSOPRAZOLE'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | 15MG/DAY | DrugDosageText | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the dosage of drug 'MOSAPRIDE'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | 5MG/DAY | DrugDosageText | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the outcome of reaction 'Acute myocardial infarction'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | Recovered | ReactionOutcome | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
What was the outcome of reaction 'Coronary artery embolism'? | Acute Coronary and Cerebral Emboli From a Pedunculated Ascending Aorta Thrombus.
Hyperprolactinemia is a risk factor for thrombus formation. We present a rare case of a mobile ascending aorta thrombus leading to acute myocardial infarction and cerebral infarction in a patient with idiopathic hyperprolactinemia. (Level ... | Recovered | ReactionOutcome | CC BY-NC-ND | 34401758 | 19,729,539 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study.
Patients with immune-mediated diseases treated with CD20 inhibitors may have worse COVID-19 outcomes due to impaired humoral immunity, but differences versus the general population are unknown.
We identified patie... | OCRELIZUMAB, RITUXIMAB | DrugsGivenReaction | CC BY-NC-ND | 34401883 | 19,699,840 | 2021-08-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anti-insulin antibody positive'. | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | INSULIN ASPART, INSULIN DETEMIR, INSULIN GLARGINE, INSULIN NOS | DrugsGivenReaction | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug specific antibody'. | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | INSULIN ASPART, INSULIN DETEMIR, INSULIN GLARGINE, INSULIN NOS | DrugsGivenReaction | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperglycaemia'. | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | INSULIN ASPART, INSULIN DETEMIR, INSULIN GLARGINE, INSULIN NOS | DrugsGivenReaction | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoglycaemia'. | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | INSULIN ASPART, INSULIN DETEMIR, INSULIN GLARGINE, INSULIN NOS | DrugsGivenReaction | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ketoacidosis'. | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | INSULIN ASPART, INSULIN DETEMIR, INSULIN GLARGINE, INSULIN NOS | DrugsGivenReaction | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the administration route of drug 'INSULIN ASPART'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the administration route of drug 'INSULIN DETEMIR'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the administration route of drug 'INSULIN GLARGINE'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the administration route of drug 'INSULIN NOS'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the dosage of drug 'INSULIN NOS'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | ALONG WITH REGULAR INSULIN AT MORE THAN 400 UNITS PER DAY | DrugDosageText | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the outcome of reaction 'Anti-insulin antibody positive'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Recovering | ReactionOutcome | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the outcome of reaction 'Drug specific antibody'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Recovering | ReactionOutcome | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the outcome of reaction 'Hyperglycaemia'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Recovering | ReactionOutcome | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the outcome of reaction 'Hypoglycaemia'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Recovering | ReactionOutcome | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
What was the outcome of reaction 'Ketoacidosis'? | Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed Type 1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy.
Exogenous insulin antibody syndrome (EIAS), which rarely occurs in the patient with type 1 diabetes, results in antibody-induced insulin resistance, hypergly... | Recovering | ReactionOutcome | CC BY-NC | 34403116 | 20,130,557 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,941,210 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eosinophilic fasciitis'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal stiffness'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nodal osteoarthritis'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain in extremity'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin discolouration'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin induration'. | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | CARBOPLATIN, CEMIPLIMAB-RWLC | DrugsGivenReaction | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Arthralgia'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Condition aggravated'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Eosinophilic fasciitis'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Musculoskeletal stiffness'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Nodal osteoarthritis'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Pain in extremity'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Skin discolouration'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
What was the outcome of reaction 'Skin induration'? | Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.
BACKGROUND Eosinophilic fasciitis, also known as Shulman syndrome, is a rare inflammatory condition characterized by diffuse erythema and progressive collagenous thickening of the subcutaneous fascia. The underlyin... | Recovered | ReactionOutcome | CC BY-NC-ND | 34403405 | 19,752,452 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.
BACKGROUND
Haemophilus influenzae is a Gram-negative coccobacillus that can cause many different kinds of infection, ranging from mild ear infection to life-threatening dise... | ACYCLOVIR, CEFTRIAXONE, DEXAMETHASONE, DOPAMINE HYDROCHLORIDE, HUMAN PLASMA, MEROPENEM, PHYTONADIONE, SODIUM CHLORIDE | DrugsGivenReaction | CC BY | 34404462 | 20,597,784 | 2021-08-18 |
What was the administration route of drug 'CEFTRIAXONE'? | Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.
BACKGROUND
Haemophilus influenzae is a Gram-negative coccobacillus that can cause many different kinds of infection, ranging from mild ear infection to life-threatening dise... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34404462 | 20,597,784 | 2021-08-18 |
What was the administration route of drug 'SODIUM CHLORIDE'? | Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.
BACKGROUND
Haemophilus influenzae is a Gram-negative coccobacillus that can cause many different kinds of infection, ranging from mild ear infection to life-threatening dise... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34404462 | 20,597,784 | 2021-08-18 |
What was the dosage of drug 'MEROPENEM'? | Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.
BACKGROUND
Haemophilus influenzae is a Gram-negative coccobacillus that can cause many different kinds of infection, ranging from mild ear infection to life-threatening dise... | 120 MILLIGRAM/KILOGRAM, QD | DrugDosageText | CC BY | 34404462 | 20,597,784 | 2021-08-18 |
What was the dosage of drug 'SODIUM CHLORIDE'? | Beta-lactamase-negative ampicillin-resistant Haemophilus influenzae type b meningitis in partially immunized immunocompetent child: a case report.
BACKGROUND
Haemophilus influenzae is a Gram-negative coccobacillus that can cause many different kinds of infection, ranging from mild ear infection to life-threatening dise... | 2 BOLUSES | DrugDosageText | CC BY | 34404462 | 20,597,784 | 2021-08-18 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Treatment with Granulocyte-colony Stimulating Factor (G-CSF) is not associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast Cancer.
Background: Survival outcome after developing brain metastasis is poor and there is an unmet need to identify factors that can promote brain metastasis.... | FILGRASTIM | DrugsGivenReaction | CC BY | 34405029 | 19,985,550 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to central nervous system'. | Treatment with Granulocyte-colony Stimulating Factor (G-CSF) is not associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast Cancer.
Background: Survival outcome after developing brain metastasis is poor and there is an unmet need to identify factors that can promote brain metastasis.... | FILGRASTIM | DrugsGivenReaction | CC BY | 34405029 | 19,985,550 | 2021 |
What was the outcome of reaction 'Death'? | Treatment with Granulocyte-colony Stimulating Factor (G-CSF) is not associated with Increased Risk of Brain Metastasis in Patients with De Novo Stage IV Breast Cancer.
Background: Survival outcome after developing brain metastasis is poor and there is an unmet need to identify factors that can promote brain metastasis.... | Fatal | ReactionOutcome | CC BY | 34405029 | 19,985,550 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated myositis'. | A Rapidly Debilitating Myopathy: A Rare Case of Statin-Induced Necrotizing Myositis.
Statins are well tolerated in general but can be associated with myopathies. Statin-induced myopathies can range widely from mild myalgias to necrotizing autoimmune myopathies. We present a case of an 81-year-old man on statins for fiv... | DEXAMETHASONE, ROSUVASTATIN | DrugsGivenReaction | CC BY | 34405065 | 19,778,862 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rhabdomyolysis'. | A Rapidly Debilitating Myopathy: A Rare Case of Statin-Induced Necrotizing Myositis.
Statins are well tolerated in general but can be associated with myopathies. Statin-induced myopathies can range widely from mild myalgias to necrotizing autoimmune myopathies. We present a case of an 81-year-old man on statins for fiv... | DEXAMETHASONE, ROSUVASTATIN | DrugsGivenReaction | CC BY | 34405065 | 19,778,862 | 2021-07 |
What was the dosage of drug 'DEXAMETHASONE'? | A Rapidly Debilitating Myopathy: A Rare Case of Statin-Induced Necrotizing Myositis.
Statins are well tolerated in general but can be associated with myopathies. Statin-induced myopathies can range widely from mild myalgias to necrotizing autoimmune myopathies. We present a case of an 81-year-old man on statins for fiv... | TAPERING DOSE | DrugDosageText | CC BY | 34405065 | 19,778,862 | 2021-07 |
What was the outcome of reaction 'Immune-mediated myositis'? | A Rapidly Debilitating Myopathy: A Rare Case of Statin-Induced Necrotizing Myositis.
Statins are well tolerated in general but can be associated with myopathies. Statin-induced myopathies can range widely from mild myalgias to necrotizing autoimmune myopathies. We present a case of an 81-year-old man on statins for fiv... | Not recovered | ReactionOutcome | CC BY | 34405065 | 19,778,862 | 2021-07 |
What was the outcome of reaction 'Rhabdomyolysis'? | A Rapidly Debilitating Myopathy: A Rare Case of Statin-Induced Necrotizing Myositis.
Statins are well tolerated in general but can be associated with myopathies. Statin-induced myopathies can range widely from mild myalgias to necrotizing autoimmune myopathies. We present a case of an 81-year-old man on statins for fiv... | Not recovered | ReactionOutcome | CC BY | 34405065 | 19,778,862 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34405092 | 19,766,060 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | DEXAMETHASONE, REMDESIVIR | DrugsGivenReaction | CC BY-NC-ND | 34405092 | 20,289,198 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Humoral immune defect'. | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34405092 | 19,766,060 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | AMOXICILLIN\CLAVULANIC ACID, AZITHROMYCIN, CASIRIVIMAB\IMDEVIMAB, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, HUMAN IMMUNOGLOBULIN G, METHOTREXATE, REMDESIVIR, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | DEXAMETHASONE SODIUM PHOSPHATE | DrugsGivenReaction | CC BY-NC-ND | 34405092 | 20,261,841 | 2021-08 |
What was the administration route of drug 'CASIRIVIMAB\IMDEVIMAB'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | Other | DrugAdministrationRoute | CC BY-NC-ND | 34405092 | 20,306,650 | 2021-08 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | HYPERFRACTIONATED | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'CYTARABINE'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | HIGH-DOSE (HYPER-CVAD REGIMEN) | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'DEXAMETHASONE'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | AS OFF-LABEL TREATMENT FOR COVID-19 PNEUMONIA | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'DOXORUBICIN'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | HYPER CVAD ALTERNATING WITH HD MTX/ARAC REGIMEN | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'METHOTREXATE'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | HIGH-DOSE (HYPER-CVAD REGIMEN) | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the dosage of drug 'RITUXIMAB'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | MAINTENANCE THERAPY | DrugDosageText | CC BY-NC-ND | 34405092 | 20,239,352 | 2021-08 |
What was the outcome of reaction 'COVID-19 pneumonia'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | Recovered | ReactionOutcome | CC BY-NC-ND | 34405092 | 20,325,214 | 2021-08 |
What was the outcome of reaction 'COVID-19'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | Recovered | ReactionOutcome | CC BY-NC-ND | 34405092 | 19,766,060 | 2021-08 |
What was the outcome of reaction 'Hypogammaglobulinaemia'? | Successful Treatment of Persistent Coronavirus Disease 2019 Infection in a Patient With Hypogammaglobulinemia With REGN-COV2: A Case Report.
A 55-year-old man with hypogammaglobulinemia due to previous rituximab treatment developed persistent coronavirus disease 2019 pneumonia. Treatment with REGN-COV2 (casirivimab and... | Recovered | ReactionOutcome | CC BY-NC-ND | 34405092 | 20,325,214 | 2021-08 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cushingoid'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | PREDNISONE | DrugsGivenReaction | CC BY | 34405257 | 20,518,712 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | PREDNISONE | DrugsGivenReaction | CC BY | 34405257 | 20,518,712 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'General physical health deterioration'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | COLCHICINE, PREDNISONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY | 34405257 | 20,553,975 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Insomnia'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | COLCHICINE, PREDNISONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY | 34405257 | 20,553,975 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product use issue'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY | 34405257 | 19,812,575 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Irritability'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | COLCHICINE, PREDNISONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY | 34405257 | 20,558,027 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mood swings'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | TRIAMCINOLONE | DrugsGivenReaction | CC BY | 34405257 | 20,553,961 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | COLCHICINE, GENTAMICIN, HUMAN IMMUNOGLOBULIN G, PREDNISONE, TRIAMCINOLONE | DrugsGivenReaction | CC BY | 34405257 | 20,545,549 | 2021-08-17 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pericardial effusion'. | The Efficacy, Safety, and Side Effects of Intrapericardial Triamcinolone Treatment in Children with Post-surgical Pericardial Effusion: A Case Series.
Intrapericardial triamcinolone can be used to treat chronic pericardial effusion (PE) in adults; however, pediatric data are lacking. In this case series we aim to evalu... | PREDNISONE | DrugsGivenReaction | CC BY | 34405257 | 20,518,712 | 2021-08-17 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.